Keele Research Repository
Explore the Repository
Meijboom, KE, Volpato, V, Monzón-Sandoval, J, Hoolachan, JM, Hammond, SM, Abendroth, F, de Jong, OG, Hazell, G, Ahlskog, N, Wood, MJA, Webber, C and Bowerman, M (2021) Combining multi-omics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight, 6 (13). pp. 1-24. ISSN 2379-3708
Clean Copy - No changes indicated.pdf - Accepted Version
Download (2MB) | Preview
© 2021, Meijboom et al.pdf - Published Version
Download (9MB) | Preview
Abstract
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including lifespan, weight and key molecular networks in skeletal muscle. Our work highlights the potential of multiple and parallel data driven approaches for the development of novel treatments for use in combination with SMN restoration therapies.
Item Type: | Article |
---|---|
Additional Information: | © 2021, Meijboom et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. |
Subjects: | R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
Divisions: | Faculty of Medicine and Health Sciences > School of Medicine |
Depositing User: | Symplectic |
Date Deposited: | 19 May 2021 09:01 |
Last Modified: | 21 Sep 2021 15:02 |
URI: | https://eprints.keele.ac.uk/id/eprint/9590 |